Company

Evolus, Inc.

Headquarters: Newport Beach, CA, United States

Employees: 167

CEO: Mr. David Moatazedi

NASDAQ: EOLS -0.22%

Market Cap

$435.6 Million

USD as of Jan. 1, 2026

Market Cap History

Evolus, Inc. Categories

United States Healthcare Drug Manufacturers—Specialty & Generic
United States Healthcare United States Drug Manufacturers—Specialty & Generic

Evolus, Inc. market capitalization over time

Evolution of Evolus, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Evolus, Inc.

Top Competitors by Market Capitalization

Industry: Drug Manufacturers—Specialty & Generic

Company	Market Cap (USD)
MERCK Kommanditgesellschaft auf Aktien	$62.01 B
Zoetis Inc.	$55.81 B
Takeda Pharmaceutical Company Limited	$45.42 B
Haleon plc	$44.50 B
Teva Pharmaceutical Industries Limited	$35.85 B

Sector:

Company	Market Cap (USD)
Lilly	$968.50 B
Johnson & Johnson	$499.57 B
AbbVie	$405.28 B
Roche	$332.12 B
UnitedHealth Group	$304.72 B

Detailed Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

⛩️ Moltgate

Spam is free. Your attention isn’t.

Turn your inbox into a paid channel. Set your price lanes $10 / $30 / $100 and only get messages worth reading.

Get Started Free

Built for busy humans + 🦞 AI agents. Plain-text only.

Financials

Last Financial Reports Date	Dec. 31, 2023
Revenue TTM	$202.1 M
EBITDA	$-30,974,000
Gross Profit TTM	$140.5 M
Profit Margin	-30.52%
Operating Margin	-8.33%
Quarterly Revenue Growth	39.80%